Takasaki, Japan

Teruyuki Saki

This inventor holds 1 USPTO granted patent. Top assignee: Nps Pharmaceuticals, Inc.. Active years: 2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Teruyuki Saki. Retrieved from https://idiyas.com/inventor/teruyuki-saki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Teruyuki Saki

Introduction

Teruyuki Saki is a notable inventor based in Takasaki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of calcium receptor active compounds. His work has the potential to impact various therapeutic areas.

Latest Patents

Saki holds a patent for a novel calcium receptor active compound. The formula provided in his patent is Ar—[CRR]—X—[CRR]—[CRR]—NR—[CRR]—Ar. This innovation showcases his expertise in medicinal chemistry and receptor biology.

Career Highlights

Saki is currently employed at NPS Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work at the company reflects his commitment to improving healthcare through innovative solutions.

Collaborations

Some of his notable coworkers include Atsuya Takami and Rika Nagao. Their collaboration has likely contributed to the success of Saki's projects and innovations.

Conclusion

Teruyuki Saki's contributions to the field of pharmaceuticals, particularly through his patent on calcium receptor active compounds, highlight his role as an influential inventor. His work continues to pave the way for advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…